Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

The flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside is able to protect endothelial cells by a direct antioxidant effect.

Lemmens KJ, van de Wier B, Vaes N, Ghosh M, van Zandvoort MA, van der Vijgh WJ, Bast A, Haenen GR.

Toxicol In Vitro. 2014 Jun;28(4):538-43. doi: 10.1016/j.tiv.2013.12.019.

PMID:
24412621
2.

The contribution of the major metabolite 4'-O-methylmonoHER to the antioxidant activity of the flavonoid monoHER.

Lemmens KJ, Herst PM, Housmans BA, Moalin M, van der Vijgh WJ, Bast A, Haenen GR.

Chem Biol Interact. 2015 Sep 5;239:146-52. doi: 10.1016/j.cbi.2015.07.004.

PMID:
26163455
3.

Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.

Jacobs H, Peters R, den Hartog GJ, van der Vijgh WJ, Bast A, Haenen GR.

Drug Metab Dispos. 2011 May;39(5):750-6. doi: 10.1124/dmd.110.036525.

4.

An essential difference between the flavonoids monoHER and quercetin in their interplay with the endogenous antioxidant network.

Jacobs H, Moalin M, Bast A, van der Vijgh WJ, Haenen GR.

PLoS One. 2010 Nov 8;5(11):e13880. doi: 10.1371/journal.pone.0013880.

5.

Differences in pharmacological activities of the antioxidant flavonoid monoHER in humans and mice are caused by variations in its metabolic profile.

Jacobs H, Koek GH, Peters R, Moalin M, Tack J, van der Vijgh WJ, Bast A, Haenen GR.

Clin Pharmacol Ther. 2011 Dec;90(6):852-9. doi: 10.1038/clpt.2011.200.

PMID:
22048223
6.

The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuclear factor-κB.

Jacobs H, Bast A, Peters GJ, van der Vijgh WJ, Haenen GR.

Br J Cancer. 2011 Feb 1;104(3):437-40. doi: 10.1038/sj.bjc.6606065.

7.

Characterization of the glutathione conjugate of the semisynthetic flavonoid monoHER.

Jacobs H, van der Vijgh WJ, Koek GH, Draaisma GJ, Moalin M, van Strijdonck GP, Bast A, Haenen GR.

Free Radic Biol Med. 2009 Jun 15;46(12):1567-73. doi: 10.1016/j.freeradbiomed.2009.02.031.

PMID:
19272444
8.

Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.

van Acker SA, Boven E, Kuiper K, van den Berg DJ, Grimbergen JA, Kramer K, Bast A, van der Vijgh WJ.

Clin Cancer Res. 1997 Oct;3(10):1747-54.

9.

An essential difference in the reactivity of the glutathione adducts of the structurally closely related flavonoids monoHER and quercetin.

Jacobs H, Moalin M, van Gisbergen MW, Bast A, van der Vijgh WJ, Haenen GR.

Free Radic Biol Med. 2011 Dec 1;51(11):2118-23. doi: 10.1016/j.freeradbiomed.2011.09.013.

PMID:
21982895
10.

The flavonoid monoHER promotes the adaption to oxidative stress during the onset of NAFLD.

Lemmens KJ, van de Wier B, Koek GH, Köhler E, Drittij MJ, van der Vijgh WJ, Bast A, Haenen GR.

Biochem Biophys Res Commun. 2015 Jan 2;456(1):179-82. doi: 10.1016/j.bbrc.2014.11.055.

PMID:
25462563
11.

The flavonoid monoHER prevents monocrotaline-induced hepatic sinusoidal injury in rats.

Ezzat T, van den Broek MA, Davies N, Dejong CH, Bast A, Malagó M, Dhar DK, Olde Damink SW.

J Surg Oncol. 2012 Jul 1;106(1):72-8. doi: 10.1002/jso.23046.

PMID:
22287334
12.
13.

The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro.

Abou El Hassan MA, Verheul HM, Jorna AS, Schalkwijk C, van Bezu J, van der Vijgh WJ, Bast A.

Br J Cancer. 2003 Jul 21;89(2):357-62.

14.

The cocoa flavanol (-)-epicatechin protects the cortisol response.

Ruijters EJ, Haenen GR, Weseler AR, Bast A.

Pharmacol Res. 2014 Jan;79:28-33. doi: 10.1016/j.phrs.2013.11.004.

PMID:
24269961
15.

The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.

Bruynzeel AM, Mul PP, Berkhof J, Bast A, Niessen HW, van der Vijgh WJ.

Cancer Chemother Pharmacol. 2006 Nov;58(5):699-702.

PMID:
16565833
16.

o-(beta-Hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(II)/hyperthermia treatment.

Bull JM, Strebel FR, Sunderland BA, Bulger RE, Edwards M, Siddik ZH, Newman RA.

Cancer Res. 1988 Apr 15;48(8):2239-44.

17.
18.

Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).

Gonzalez-Covarrubias V, Kalabus JL, Blanco JG.

Pharm Res. 2008 Jul;25(7):1730-4. doi: 10.1007/s11095-008-9592-5.

19.

Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.

van Acker SA, Kramer K, Grimbergen JA, van den Berg DJ, van der Vijgh WJ, Bast A.

Br J Pharmacol. 1995 Aug;115(7):1260-4.

20.

Effect of tri- and tetra-O-(beta-hydroxyethyl)-rutoside on red blood cell aggregation of human blood.

van Haeringen NJ.

Bibl Anat. 1975;13:197-9. No abstract available.

PMID:
1231726

Supplemental Content

Support Center